Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2016—Astute Medical said in a statement that a new ancillary analysis of two multicenter studies using the company’s NephroCheck Test demonstrates that urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases 2 (TIMP-2), the biomarkers detected and measured by the test, accurately predict acute kidney injury in septic patients with or without other organ failures.
September 2016—Thermo Scientific introduced two large-capacity blood banking centrifuge models. For regular- to medium-throughput blood processing needs, the Sorvall BP 8 and Heraeus Cryofuge 8 centrifuges provide 6 × 550 mL blood bag capacity and, using the same bucket system, are upgradeable to 8 × 550 mL bags.
September 2016—BrandTech introduced a line of Blaubrand class A, USP-certified volumetric glassware from Brand GmbH & Co. KG. The line includes clear and amber volumetric flasks, graduated cylinders, bulb pipettes, and volumetric pipettes.
September 2016—Leica Biosystems added four sizes of Surgipath AffirmSeal jars. The new sizes, 40 mL, 60 mL, 90 mL, and 120 mL, are offered in multiple packaging configurations. Prefilled with 10 percent neutral buffered formalin, the jars are specifically designed for safe collection and transport of various sized specimens.
September 2016—The Oncomine Lung Cell-Free DNA Assay from Thermo Fisher Scientific is designed to target mutations in non-small cell lung cancer samples derived from circulating cfDNA in blood.
September 2016—Aesku Group has received FDA 510(k) clearance for its Helios Automated IFA System with Aeskuslides ANA HEp-2-Gamma Assay.
September 2016—SpeeDx received CE-IVD marking for its PlexPCR HSV-1&2, VZV multiplex qPCR kit. The multiplex molecular diagnostic test offers a single-well solution to cover the detection and differentiation of three herpes viruses (HSV-1, HSV-2, VZV) in addition to an internal control.
September 2016—Roche announced the worldwide launch of the Heat-Seq Target Enrichment Systems, which provide rapid and accurate enrichment methods designed to improve the detection of variants in human genetics and cancer research.
September 2016—LGC Maine Standards released its Validate Tumor Markers and Validate Whole Blood Glucose calibration verification/linearity test kits.
September 2016—Streck and Biodesix, a molecular diagnostics company that develops blood-based tests in oncology, have signed an agreement to make Streck the exclusive supplier of DNA and RNA tubes for Biodesix.
